• Fri news: Pfizer’s $1B Chinese commitment. RFK Jr. and pharma. Eisai dials back Leqembi forecast. US diabetes burden increase. JNJ gets Varipulse approval. See more on our front page

Cv rare disease

Quote
anonymous said:
I think they are referring to the post about training of CV/IMM coming together. It shouldn't be a concern. I don't think CV and IMMs are coming together and if they are, they should have never let Anthony Mancini go since that was his baby.
Click to expand...
CV/IMM training is coming together. The training team was informed on Friday outlining who reports to who. No news about the salesforces combining.

Yup, once Xarelto goes generic payers will prefer the generic over Eliquis especially for new patients. I foresee restructures in CV happening once a twice a year going forward until factor 11A hit the market and if especially if Camzyos doesn’t pick up. Factor 11A could also be a hard sell if BMS doesn’t have the right pricing strategy to enter the market.
 








CV is not going to survive. Camzyos is not doing well. Eliquis reps does not have competitor reps to compete against. Definitely do not need all these reps in the community setting.
 








anonymous said:
CV is not going to survive. Camzyos is not doing well. Eliquis reps does not have competitor reps to compete against. Definitely do not need all these reps in the community setting.
Click to expand...

CV days are numbered. I predict some areas in the country that doesn’t have Speciality reps will have a few Community reps and other areas with COEs will have more of the Speciality reps to drive Camzyos. If Eliquis doesn’t increase market share by January with no competition on the market BMS will layoff in the first quarter of 2025. Additionally, Xarelto is expected to go generic by the end of this year. The company keeps saying it won’t affect us but with cost being the biggest factor in today’s market Eliquis will lose share drastically in the community setting.
 




anonymous said:
Cv is doomed with Zeposia training coming over. Heard Reps were promised cv TAS vacancies
Click to expand...
I’ve heard the same, and they are currently interviewing for the new CV Specialty roles with the expectation of hiring for these positions. Unfortunately, the CV Community TAS and current Specialty TAS are expected to train and introduce these new representatives to providers who are earning $40k-$60k more than the average CV rep, even though we will all be performing the same role. This creates a significant wage disparity. Meanwhile, CV is essentially funding BMS while not being fairly paid for selling a "rare disease" medication. I hope that CV's new leader, Joy, will bring some JOYOUS changes to our paychecks by increasing CV salaries and modifying our IC plan so that every TAS has the same ability to make bonus.
 




anonymous said:
I’ve heard the same, and they are currently interviewing for the new CV Specialty roles with the expectation of hiring for these positions. Unfortunately, the CV Community TAS and current Specialty TAS are expected to train and introduce these new representatives to providers who are earning $40k-$60k more than the average CV rep, even though we will all be performing the same role. This creates a significant wage disparity. Meanwhile, CV is essentially funding BMS while not being fairly paid for selling a "rare disease" medication. I hope that CV's new leader, Joy, will bring some JOYOUS changes to our paychecks by increasing CV salaries and modifying our IC plan so that every TAS has the same ability to make bonus.
Click to expand...
Highly unlikely, but you can keep dreaming. As long as you’re in CV, with Eliquis in the bag, you’re definitely not going to be considered ‘rare disease’
 




Can someone tell me what the role of a Senior Theraputic Area Specialist, CV, Community actually does? The role description makes it seem like an MSL position versus a true front line sales rep position. Any guidance would be appreciated.
 








anonymous said:
Can someone tell me what the role of a Senior Theraputic Area Specialist, CV, Community actually does? The role description makes it seem like an MSL position versus a true front line sales rep position. Any guidance would be appreciated.
Click to expand...
It a true front line sales role promoting Eliquis and Camzyos. There are MSLs that covers each region.
 








anonymous said:
Morale is certainly low, and many reps are feeling frustrated and anxious about job security. Since the launch of Camzyos, CV has undergone changes every 6 months. It seems that the SLT is out of touch with what needs to be done. Now, they're merging the training division CV/IMM starting this Monday.
Click to expand...
Too many changes in all divisions, senior leadership prevents any momentum from building - anywhere.
 












anonymous said:
CV is not going to survive. Camzyos is not doing well. Eliquis reps does not have competitor reps to compete against. Definitely do not need all these reps in the community setting.
Click to expand...
Maybe BMS should have thought about expanding access to Camzyos at centers where patients are seen. Seems like a no brainer.
 
























Top Bottom
Back
Quote